Markus Holzner

Markus Holzner is currently a consultant in M&A at Deloitte and a PhD student in Genetics at ETH Zürich. Previously, Markus interned at Roche, where they contributed to a project on neural disease models, leading to significant cost savings. Markus has also held roles such as Board Member at the AMB Institute of Molecular Health Sciences, advocating for PhD and PostDoc representation, and as a Student Research Fellow at the University of Oxford, where they developed anti-cancer compounds. With a strong academic background, Markus has published several papers and presented at numerous conferences while mentoring students in research methodologies.